Peroxisome proliferator-activated receptor delta agonists attenuated the C-reactive protein-induced pro-inflammation in cardiomyocytes and H9c2 cardiomyoblasts

Yao Jen Liang, Chao Yi Chen, Shiow Jen Juang, Ling Ping Lai, Kou Gi Shyu, Bao Wei Wang, Shannen Yuan Chun Liu, Jyh Gang Leu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

C-reactive protein (CRP) has emerged as a new marker for cardiovascular diseases. Activation of peroxisome proliferator-activated receptor δ (PPARδ) plays beneficial roles in cardiac disorders. However, the relationship between CRP and PPARδ in cardiac cells remains unclear. This study focused on the underlying molecular mechanisms of CRP and PPARδagonists. Cardiomyocytes and cardiomyoblast cell line (H9c2) were used in different groups: Untreated; 15μg/ml CRP with or without 1μM PPARδ agonists (L-165041). CRP increased PPARδ and interleukin-6 expression in cardiomyocytes and H9c2 cardiomyoblasts. NF-κB inducing kinase (NIK) and NF-κB pathway also activated by CRP stimulation. These changes could be inhibited by L-165041 through p38MAPK and c-JNK pathways. However, transfection with siRNA of CD32 CRP receptor did not decrease CRP signaling or reverse the effects of L-165041 in CRP-treated cardiomyocytes and H9c2. Pretreatment with L-165041 attenuated apoptosis induced by hypoxia with or without CRP in H9c2 cardiomyoblasts. CRP up-regulated PPARδ expression in cardiomyocytes and H9c2. L-165041 attenuated CRP-induced pro-inflammatory signaling through p38MAPK and c-JNK in H9c2 cardiomyoblasts. However, PPARδ activation attenuated CRP-induced NF-κB pathway may be independent of CD32. These results may provide new evidence of PPARδ beneficial effects for inflammatory cardiomyopathy.

Original languageEnglish
Pages (from-to)84-92
Number of pages9
JournalEuropean Journal of Pharmacology
Volume643
Issue number1
DOIs
Publication statusPublished - Sep 2010

Fingerprint

PPAR delta
Cardiac Myocytes
C-Reactive Protein
4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid
Inflammation
Peroxisome Proliferator-Activated Receptors
MAP Kinase Signaling System
Cardiomyopathies

Keywords

  • C-reactive protein
  • CD32
  • Inflammation
  • NF-κB
  • PPARδ

ASJC Scopus subject areas

  • Pharmacology

Cite this

Peroxisome proliferator-activated receptor delta agonists attenuated the C-reactive protein-induced pro-inflammation in cardiomyocytes and H9c2 cardiomyoblasts. / Liang, Yao Jen; Chen, Chao Yi; Juang, Shiow Jen; Lai, Ling Ping; Shyu, Kou Gi; Wang, Bao Wei; Liu, Shannen Yuan Chun; Leu, Jyh Gang.

In: European Journal of Pharmacology, Vol. 643, No. 1, 09.2010, p. 84-92.

Research output: Contribution to journalArticle

Liang, Yao Jen ; Chen, Chao Yi ; Juang, Shiow Jen ; Lai, Ling Ping ; Shyu, Kou Gi ; Wang, Bao Wei ; Liu, Shannen Yuan Chun ; Leu, Jyh Gang. / Peroxisome proliferator-activated receptor delta agonists attenuated the C-reactive protein-induced pro-inflammation in cardiomyocytes and H9c2 cardiomyoblasts. In: European Journal of Pharmacology. 2010 ; Vol. 643, No. 1. pp. 84-92.
@article{830dcf1e49ee49f1a439e0123b2e1973,
title = "Peroxisome proliferator-activated receptor delta agonists attenuated the C-reactive protein-induced pro-inflammation in cardiomyocytes and H9c2 cardiomyoblasts",
abstract = "C-reactive protein (CRP) has emerged as a new marker for cardiovascular diseases. Activation of peroxisome proliferator-activated receptor δ (PPARδ) plays beneficial roles in cardiac disorders. However, the relationship between CRP and PPARδ in cardiac cells remains unclear. This study focused on the underlying molecular mechanisms of CRP and PPARδagonists. Cardiomyocytes and cardiomyoblast cell line (H9c2) were used in different groups: Untreated; 15μg/ml CRP with or without 1μM PPARδ agonists (L-165041). CRP increased PPARδ and interleukin-6 expression in cardiomyocytes and H9c2 cardiomyoblasts. NF-κB inducing kinase (NIK) and NF-κB pathway also activated by CRP stimulation. These changes could be inhibited by L-165041 through p38MAPK and c-JNK pathways. However, transfection with siRNA of CD32 CRP receptor did not decrease CRP signaling or reverse the effects of L-165041 in CRP-treated cardiomyocytes and H9c2. Pretreatment with L-165041 attenuated apoptosis induced by hypoxia with or without CRP in H9c2 cardiomyoblasts. CRP up-regulated PPARδ expression in cardiomyocytes and H9c2. L-165041 attenuated CRP-induced pro-inflammatory signaling through p38MAPK and c-JNK in H9c2 cardiomyoblasts. However, PPARδ activation attenuated CRP-induced NF-κB pathway may be independent of CD32. These results may provide new evidence of PPARδ beneficial effects for inflammatory cardiomyopathy.",
keywords = "C-reactive protein, CD32, Inflammation, NF-κB, PPARδ",
author = "Liang, {Yao Jen} and Chen, {Chao Yi} and Juang, {Shiow Jen} and Lai, {Ling Ping} and Shyu, {Kou Gi} and Wang, {Bao Wei} and Liu, {Shannen Yuan Chun} and Leu, {Jyh Gang}",
year = "2010",
month = "9",
doi = "10.1016/j.ejphar.2010.06.031",
language = "English",
volume = "643",
pages = "84--92",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor delta agonists attenuated the C-reactive protein-induced pro-inflammation in cardiomyocytes and H9c2 cardiomyoblasts

AU - Liang, Yao Jen

AU - Chen, Chao Yi

AU - Juang, Shiow Jen

AU - Lai, Ling Ping

AU - Shyu, Kou Gi

AU - Wang, Bao Wei

AU - Liu, Shannen Yuan Chun

AU - Leu, Jyh Gang

PY - 2010/9

Y1 - 2010/9

N2 - C-reactive protein (CRP) has emerged as a new marker for cardiovascular diseases. Activation of peroxisome proliferator-activated receptor δ (PPARδ) plays beneficial roles in cardiac disorders. However, the relationship between CRP and PPARδ in cardiac cells remains unclear. This study focused on the underlying molecular mechanisms of CRP and PPARδagonists. Cardiomyocytes and cardiomyoblast cell line (H9c2) were used in different groups: Untreated; 15μg/ml CRP with or without 1μM PPARδ agonists (L-165041). CRP increased PPARδ and interleukin-6 expression in cardiomyocytes and H9c2 cardiomyoblasts. NF-κB inducing kinase (NIK) and NF-κB pathway also activated by CRP stimulation. These changes could be inhibited by L-165041 through p38MAPK and c-JNK pathways. However, transfection with siRNA of CD32 CRP receptor did not decrease CRP signaling or reverse the effects of L-165041 in CRP-treated cardiomyocytes and H9c2. Pretreatment with L-165041 attenuated apoptosis induced by hypoxia with or without CRP in H9c2 cardiomyoblasts. CRP up-regulated PPARδ expression in cardiomyocytes and H9c2. L-165041 attenuated CRP-induced pro-inflammatory signaling through p38MAPK and c-JNK in H9c2 cardiomyoblasts. However, PPARδ activation attenuated CRP-induced NF-κB pathway may be independent of CD32. These results may provide new evidence of PPARδ beneficial effects for inflammatory cardiomyopathy.

AB - C-reactive protein (CRP) has emerged as a new marker for cardiovascular diseases. Activation of peroxisome proliferator-activated receptor δ (PPARδ) plays beneficial roles in cardiac disorders. However, the relationship between CRP and PPARδ in cardiac cells remains unclear. This study focused on the underlying molecular mechanisms of CRP and PPARδagonists. Cardiomyocytes and cardiomyoblast cell line (H9c2) were used in different groups: Untreated; 15μg/ml CRP with or without 1μM PPARδ agonists (L-165041). CRP increased PPARδ and interleukin-6 expression in cardiomyocytes and H9c2 cardiomyoblasts. NF-κB inducing kinase (NIK) and NF-κB pathway also activated by CRP stimulation. These changes could be inhibited by L-165041 through p38MAPK and c-JNK pathways. However, transfection with siRNA of CD32 CRP receptor did not decrease CRP signaling or reverse the effects of L-165041 in CRP-treated cardiomyocytes and H9c2. Pretreatment with L-165041 attenuated apoptosis induced by hypoxia with or without CRP in H9c2 cardiomyoblasts. CRP up-regulated PPARδ expression in cardiomyocytes and H9c2. L-165041 attenuated CRP-induced pro-inflammatory signaling through p38MAPK and c-JNK in H9c2 cardiomyoblasts. However, PPARδ activation attenuated CRP-induced NF-κB pathway may be independent of CD32. These results may provide new evidence of PPARδ beneficial effects for inflammatory cardiomyopathy.

KW - C-reactive protein

KW - CD32

KW - Inflammation

KW - NF-κB

KW - PPARδ

UR - http://www.scopus.com/inward/record.url?scp=77955088393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955088393&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2010.06.031

DO - 10.1016/j.ejphar.2010.06.031

M3 - Article

C2 - 20599914

AN - SCOPUS:77955088393

VL - 643

SP - 84

EP - 92

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -